# A Multicenter Phase I Clinical Study of a New Compound P1446A-05 in Patients With Advanced Refractory Malignancies

> **NCT00772876** · PHASE1 · COMPLETED · sponsor: **Piramal Enterprises Limited** · enrollment: 39 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** P1446A-05

## Key facts

- **NCT ID:** NCT00772876
- **Lead sponsor:** Piramal Enterprises Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2012-04
- **Final completion:** 2012-05
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2012-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00772876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00772876, "A Multicenter Phase I Clinical Study of a New Compound P1446A-05 in Patients With Advanced Refractory Malignancies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00772876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*